Search in:

Expert Review of Clinical Pharmacology Volume 12, 2019 - Issue 8

Submit an article Journal homepage

Open access

5,340

Views

CrossRef citations to date

Altmetric

Drug Profile

Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis

Morie A. GertzDepartment of Hematology, Transplant Center, Cancer Center, Mayo Clinic College of Medicine, Rochester, MN, USACorrespondence[email protected]

https://orcid.org/0000-0002-3853-5196 View further author information

Morton ScheinbergDepartment of Rheumatology, Hospital Israelita Albert Einstein, Sao Paulo, BrazilView further author information

Márcia Waddington-CruzNeuromuscular Diseases Unit, Federal University of Rio de Janeiro, University Hospital, Rio de Janeiro, BrazilView further author information

Stephen B. HeitnerHypertrophic Cardiomyopathy Clinic, Knight Cardiovascular Institute, Portland, OR, USAView further author information

Chafic KaramDepartment of Neurology, ALS and Neuromuscular Center, Oregon Health and Science University, Portland, OR, USAView further author information

Brian DrachmanDepartment of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, USAView further author information

Sami KhellaDepartment of Neurology, University of Pennsylvania, Philadelphia, PA, USAView further author information

Carol WhelanConsultant Cardiologist, University College London-National Amyloidosis Centre, London, UKView further author information

Laura ObiciAmyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico S. Matteo, Pavia, ItalyView further author information

show all

Pages 701-711 | Received 18 Apr 2019, Accepted 19 Jun 2019, Published online: 03 Jul 2019

Cite this article
https://doi.org/10.1080/17512433.2019.1635008
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (23)

Wolfgang Poller, Susmita Sahoo, Roger Hajjar, Ulf Landmesser & Anna M. Krichevsky. (2023) Exploration of the Noncoding Genome for Human-Specific Therapeutic Targets—Recent Insights at Molecular and Cellular Level. Cells 12:22, pages 2660.
Crossref

Alejandra González-Duarte. (2023) Novel Treatments for Hereditary ATTRv Amyloidosis. JAMA 330:15, pages 1433.
Crossref

Melissa R. Tsoi, Jeffrey H. Lin & Ayan R. Patel. (2023) Emerging Therapies for Transthyretin Amyloidosis. Current Oncology Reports 25:6, pages 549-558.
Crossref

Daniele Severi, Giovanni Palumbo, Emanuele Spina, Aniello Iovino, Maria Nolano, Fiore Manganelli & Stefano Tozza. (2022) A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment. Neurological Sciences 44:4, pages 1419-1422.
Crossref

Christopher Robinson, Cynthia Pham, Alec M. Zamarripa, Chase S. Dugay, Christopher A. Lee, Amnon A. Berger, Avi Landman, Elyse M. Cornett, Hisham Kassem, Alan D. Kaye, Ivan Urits, Omar Viswanath & Latha Ganti. (2023) Inotersen to Treat Polyneuropathy Associated with Hereditary Transthyretin (hATTR) Amyloidosis. Health Psychology Research 10:5.
Crossref

Aditi Sharma, Lalit Sharma, Shouvik Kumar Nandy, Nazrana Payal, Shivam Yadav, Celia Vargas-De-La-Cruz, Md. Khalid Anwer, Haroon Khan, Tapan Behl & Simona Gabriela Bungau. (2023) Molecular Aspects and Therapeutic Implications of Herbal Compounds Targeting Different Types of Cancer. Molecules 28:2, pages 750.
Crossref

Wolfgang Poller, Bettina Heidecker, Enrico Ammirati, Andreas W. Kuss, Ana Tzvetkova, Wolfram C. Poller, Carsten Skurk & Arash Haghikia. (2023) Innate Immunity in Cardiovascular Diseases—Identification of Novel Molecular Players and Targets. Journal of Clinical Medicine 12:1, pages 335.
Crossref

Seong Jun Jo, Soon Uk Chae, Chae Bin Lee & Soo Kyung Bae. (2023) Clinical Pharmacokinetics of Approved RNA Therapeutics. International Journal of Molecular Sciences 24:1, pages 746.
Crossref

Osvaldo J. M. Nascimento, Wilson MarquesJrJr, Pedro Tomaselli & Carolina Lavigne-Moreira. 2023. Amyloidosis and Fabry Disease. Amyloidosis and Fabry Disease 5 17 .

Bożena Sosnowska, Stanisław Surma & Maciej Banach. (2022) Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy. Pharmaceuticals 15:12, pages 1573.
Crossref

Dirk Jacobus Blom, Adrian David Marais, Rajen Moodley, Nico van der Merwe, Alet van Tonder & Frederick Johan Raal. (2022) RNA-based therapy in the management of lipid disorders: a review. Lipids in Health and Disease 21:1.
Crossref

Yuki Katsuzaki, Ryo Tsukimura, Akash Chandela, Tokuhiro Chano & Yoshihito Ueno. (2022) 4′‐ C ‐Aminoethoxy‐Modified DNAs Exhibit Increased Nuclease Resistance, Sustained RNase H Activity, and Inhibition of KRAS Gene Expression . Chemistry & Biodiversity 19:8.
Crossref

Morie A. Gertz. (2022) Cardiac Amyloidosis. Heart Failure Clinics 18:3, pages 479-488.
Crossref

Julia M. Migliorati, Sunna Liu, Anna Liu, Anagha Gogate, Sreenidhi Nair, Raman Bahal, Theodore P. Rasmussen, José E. Manautou & Xiao-bo Zhong. (2022) Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration–Approved Antisense Oligonucleotide Drugs. Drug Metabolism and Disposition 50:6, pages 888-897.
Crossref

Manish Pandey, Divya Ojha, Sakshi Bansal, Ambadas B. Rode & Geetanjali Chawla. (2021) From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Molecular Aspects of Medicine 81, pages 101003.
Crossref

Julian D. GillmoreEd GaneJorg TaubelJustin KaoMarianna FontanaMichael L. MaitlandJessica SeitzerDaniel O’ConnellKathryn R. WalshKristy WoodJonathan Phillips, Yuanxin XuAdam AmaralAdam P. BoydJeffrey E. CehelskyMark D. McKeeAndrew SchiermeierOlivier HarariAndrew MurphyChristos A. KyratsousBrian ZambrowiczRandy SoltysDavid E. GutsteinJohn LeonardLaura Sepp-LorenzinoDavid Lebwohl. (2021) CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. New England Journal of Medicine 385:6, pages 493-502.
Crossref

Stanley T. Crooke, Xue-hai Liang, Rosanne M. Crooke, Brenda F. Baker & Richard S. Geary. (2021) Antisense drug discovery and development technology considered in a pharmacological context. Biochemical Pharmacology 189, pages 114196.
Crossref

Stanley T. Crooke, Brenda F. Baker, Rosanne M. Crooke & Xue-hai Liang. (2021) Antisense technology: an overview and prospectus. Nature Reviews Drug Discovery 20:6, pages 427-453.
Crossref

Dillon T. Flood, Kyle W. Knouse, Julien C. Vantourout, Seiya Kitamura, Brittany B. Sanchez, Emily J. Sturgell, Jason S. Chen, Dennis W. Wolan, Phil S. Baran & Philip E. Dawson. (2020) Synthetic Elaboration of Native DNA by RASS (SENDR). ACS Central Science 6:10, pages 1789-1799.
Crossref

Borut Peterlin, Francesca Gualandi, Ales Maver, Serenella Servidei, Silvère M. van der Maarel, Francoise Lamy, Alexander Mejat, Teresinha Evangelista & Alessandra Ferlini. (2020) Genetic testing offer for inherited neuromuscular diseases within the EURO-NMD reference network: A European survey study. PLOS ONE 15:9, pages e0239329.
Crossref

Sebastiaan HC Klaassen, Dirk J van Veldhuisen, Hans LA Nienhuis, Maarten P van den Berg, Bouke PC Hazenberg & Peter van der Meer. (2020) Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?. Cardiac Failure Review 6.
Crossref

Dinesh Babu Uthaya Kumar & Adam Williams. (2020) Long non-coding RNAs in immune regulation and their potential as therapeutic targets. International Immunopharmacology 81, pages 106279.
Crossref

Leanna Chan & Toshifumi Yokota. 2020. Gapmers. Gapmers 21 47 .

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis

Articles from other publishers (23)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis

Citations (23)

Articles from other publishers (23)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date